News for FibroGen, Inc. (1FG.F)

Hagens Berman urges XL Fleet Corp. (NYSE: XL) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims.

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company")(NASDAQ: FGEN). Such investors are...

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.46%

Stocks that traded heavily or had substantial price changes Tuesday: FibroGen, 3D Systems fall; Kontoor Brands, Square rise

Toward the end of trading Tuesday, the Dow traded up 0.08% to 31,562.10 while the NASDAQ fell 0.87% to 13,470.33. The S&P also fell, dropping 0.14% to ...

Following the market opening Tuesday, the Dow traded up 0.04% to 31,549.29 while the NASDAQ fell 0.52% to 13,518.42. The S&P also fell, dropping 0.20% ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Ma...

Today's Daily Dose brings you news about the regulatory set back of Athenex's oral Paclitaxel and CorMedix's Defencath, ASLAN Pharma's Atopic Dermatitis trial results, FDA panel review of FibroGen's Roxadustat, Morphic Therapeutic's Phase 1 single ascending dose clinical trial of MORF-057, which is in development for the treatment of inflammatory bowel disease, and STRATA Skin's CEO transition.

Mailing Address 409 ILLINOIS STREET SAN FRANCISCO CA 94158 Business Address 409 ILLINOIS STREET SAN FRANCISCO CA 94158 415-978-1200 CIK : 0000921299 (see all ...

Most Food and Drug Administration decisions scheduled for February were positive, and more importantly five new molecular entities passed FDA must...

Most Food and Drug Administration decisions scheduled for February were positive, and more importantly five new molecular entities passed FDA muster. NME ...

Biotech stocks extended their losses in the week ended Feb. 26 amid continued weakness in the broader market. Earnings came in thick and fast, with a skew ...